Embla Medical hf reports developments as a global provider of mobility solutions for prosthetics, neuro orthotics, bracing and supports, and orthotic and prosthetic patient care. Its recurring updates cover the Össur, FIOR & GENTZ, College Park and ForMotion businesses, including segment growth, manufacturing efficiency, product innovation and patient-care network activity.
Company news also includes interim financial reports, guidance, share buybacks, capital-structure items and completed acquisitions, including the majority stake in Streifeneder ortho.production. Regulatory and reimbursement developments may address access to bionic prosthetic technologies, such as U.S. Medicare coverage policies for lower-limb amputee patients.
Embla Medical (Nasdaq Copenhagen: EMBLA) announced that the Centers for Medicare & Medicaid Services has expanded access to high activity K3 knees for active K2 lower-limb amputees in the United States. This decision, effective September 1, 2024, allows a large patient group to access bionic knee technology, previously restricted to K3 and K4 functional level amputees.
The policy change follows extensive research showing that advanced prosthetic devices lead to significant clinical benefits for active K2 amputees, including reduced fall rates and improved mobility. To qualify, healthcare professionals must document that a bionic knee would improve the patient's functional health outcomes. The coverage may also include access to compatible high active K3 foot solutions.
Embla Medical's CEO, Sveinn Sölvason, welcomed the decision, stating it will greatly improve the lives of active K2 lower-limb amputees, helping them become more independent in daily activities.